Amicus Therapeutics, Inc. $FOLD Stock Position Raised by Virtus Investment Advisers LLC

by · The Cerbat Gem

Virtus Investment Advisers LLC lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 103.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 72,025 shares of the biopharmaceutical company’s stock after buying an additional 36,655 shares during the quarter. Virtus Investment Advisers LLC’s holdings in Amicus Therapeutics were worth $413,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Mackenzie Financial Corp grew its position in Amicus Therapeutics by 89.4% in the first quarter. Mackenzie Financial Corp now owns 42,605 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 20,107 shares in the last quarter. XTX Topco Ltd boosted its holdings in Amicus Therapeutics by 177.1% in the first quarter. XTX Topco Ltd now owns 106,773 shares of the biopharmaceutical company’s stock worth $871,000 after purchasing an additional 68,245 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Amicus Therapeutics during the first quarter worth $1,533,000. PNC Financial Services Group Inc. increased its position in Amicus Therapeutics by 211.4% during the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 3,497 shares during the last quarter. Finally, Legacy Capital Group California Inc. raised its holdings in Amicus Therapeutics by 16.2% during the first quarter. Legacy Capital Group California Inc. now owns 26,993 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 3,764 shares in the last quarter.

Amicus Therapeutics Stock Down 0.8%

FOLD stock opened at $9.94 on Friday. The business’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $7.39. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The company has a market cap of $3.07 billion, a PE ratio of -82.78 and a beta of 0.66. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $10.57.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.05. The company had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.Amicus Therapeutics’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. The Goldman Sachs Group upped their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.57.

View Our Latest Stock Report on Amicus Therapeutics

Insider Buying and Selling at Amicus Therapeutics

In other news, insider David Michael Clark sold 25,643 shares of Amicus Therapeutics stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93. Following the sale, the insider directly owned 322,618 shares in the company, valued at approximately $3,068,097.18. The trade was a 7.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.16, for a total transaction of $773,765.28. Following the completion of the sale, the insider directly owned 439,318 shares in the company, valued at approximately $4,463,470.88. The trade was a 14.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 201,652 shares of company stock valued at $2,019,288 over the last quarter. 2.20% of the stock is currently owned by insiders.

About Amicus Therapeutics

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

See Also

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).